GlassScriptPhysician profile
Hannah Sheppard
NPI 1760117162
$4,452.87
in general payments reported to CMS, 2019-2025
36 companies · $21.32 in 2025
The $21.32 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $498 · 2023: $2,330 · 2024: $1,604 · 2025: $21.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,932 · Education: $22.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,932.46 |
| Education | $22.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $597.29 | 2022-2024 | |
| Biogen, INC. | $489.28 | 2022-2024 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $411.13 | 2022-2024 | |
| Ucb, INC. | $377.26 | 2022-2024 | Briviact, Nayzilam, Fintepla |
| Lilly USA, LLC | $367.23 | 2022-2024 | Kisunla, Emgality, Amyvid |
| Teva Pharmaceuticals USA, INC. | $234.63 | 2022-2024 | Austedo Xr, Ajovy, Austedo |
| Alexion Pharmaceuticals, INC. | $229.24 | 2022-2024 | Soliris, Ultomiris |
| Celgene Corporation | $174.02 | 2022-2023 | Zeposia |
| Neurocrine Biosciences, INC. | $141.67 | 2023-2024 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $139.11 | 2023 | Rexulti, Nuedexta |
| Pfizer INC. | $135.58 | 2023-2024 | |
| Tg Therapeutics, INC. | $129.32 | 2023-2024 | |
| Argenx US, INC. | $114.38 | 2022-2023 | Vyvgart |
| Genzyme Corporation | $106.78 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.94 | 2022-2024 | Hyqvia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $97.27 | 2023-2024 | Uplizna, Aimovig |
| Jazz Pharmaceuticals INC. | $71.27 | 2022-2024 | |
| Philips North America LLC | $67.30 | 2024-2025 | (8874) Incourage, Vest Therapy Und, (Ak6) Vest Therapy |
| Catalyst Pharmaceuticals, INC. | $62.75 | 2023-2024 | Fycompa |
| Lundbeck LLC | $46.44 | 2023-2024 | Rexulti |
| Neurelis, INC. | $38.36 | 2022-2023 | Valtoco |
| Sk Life Science, INC. | $32.73 | 2023 | Xcopri |
| Biohaven Pharmaceutical Holding Company LTD. | $31.86 | 2022 | |
| Merz Pharmaceuticals, LLC | $27.81 | 2024 | Xeomin |
| Impel Pharmaceuticals INC. | $22.74 | 2023 | Trudhesa |
| Horizon Therapeutics Plc | $22.19 | 2023 | Uplizna |
| Alnylam Pharmaceuticals INC. | $22.17 | 2023 | Onpattro |
| Eisai INC. | $20.91 | 2024 | |
| Corium, LLC | $20.03 | 2023 | Adlarity |
| Xeris Pharmaceuticals, INC. | $19.55 | 2024 | Keveyis |
| Csl Behring | $19.54 | 2023 | Hizentra |
| Genentech USA, INC. | $19.15 | 2023 | Enspryng, Ocrevus |
| Tanabe Pharma America, INC. | $17.99 | 2023 | |
| Azurity Pharmaceuticals, INC. | $15.66 | 2024 | Horizant |
| Acadia Pharmaceuticals INC | $14.72 | 2024 | Nuplazid |
| Kyowa Kirin, INC. | $14.57 | 2024 | Nourianz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Sheppard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.